Evidence map›Paper›PMID 34684010›Full record

ArticlePharmaceutics2021

Hydrophilic Excipient-Independent Drug Release from SLA-Printed Pellets.

Lei Xu, Qingliang Yang, Wei Qiang, Huijie Li, Weizhen Zhong, Siying Pan, Gensheng Yang

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. 3D-printed dosage forms for oral administration: a review.Drug delivery and translational research · 2024
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lei XuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Qingliang YangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0002-6905-8484
Wei QiangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Huijie LiCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Weizhen ZhongCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Siying PanCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Gensheng YangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0002-6127-7930

Funding

National Natural Science Foundation of China No. 21808206; No.22078297Zhejiang Provincial Natural Science Foundation LY20B060007, LY19B060012
6 · The paper itself

Abstract

Three-dimensional (3D) printing technology, specifically stereolithography (SLA) technology, has recently created exciting possibilities for the design and fabrication of sophisticated dosages for oral administration, paving a practical way to precisely manufacture customized pharmaceutical dosages with both personalized properties and sustained drug release behavior. However, the sustained drug release achieved in prior studies largely relies on the presence of hydrophilic excipients in the printing formulation, which unfortunately impedes the printability and formability of the corresponding printing formulations. The current study developed and prepared mini-sized oral pellets using the SLA technique and successfully accomplished a hydrophilic excipient-independent drug release behavior. With ibuprofen as the model drug, the customized photopolymerizable printing formulation included polyethylene glycol diacrylate (PEGDA) as a monomer and diphenyl (2,4,6-trimethylbenzoyl) phosphine oxide (TPO) as a photoinitiator. The produced mini-sized pellets were thoroughly investigated for various factors, including their printability, physical properties, microscopic features, drug content, and drug-release profiles. The drug release profiles from the printed pellets that were larger size (3 mm and 6 mm) followed the Ritger-Peppas model, demonstrating that the release was influenced by both the diffusion of the dissolved drug and by the erosion of the hydrophilic excipients (PEG400). The profiles from the smaller printed pellets (1 mm and 2 mm) followed first release kinetics, not only illustrating that the release was impacted only by drug diffusion, but also indicating that there is a size boundary between the dependent and independent hydrophilic excipients. These results could create practical benefits to the pharmaceutical industry in terms of the design and development personalized dosages using the SLA printing technique with controllable drug release by manipulating size alone.

Indexed as

3D printed oral dosage formsmini-sized pelletsmodified releasestereolithographythree-dimensional printing

Identifiers

PMID34684010
PMCPMC8541594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.